Levels of plasma homocysteine in persons with spinal cord injury

Journal of Spinal Cord Medicine

Volumn 24, Issue 2, 2001, Pages 81-86

  Bauman, William A ^a,b,c,d   Adkins, Rodney H ^d   Spungen, Ann M ^a,b,d   Waters, Robert L ^d,e   Kemp, Bryan ^d,e   Herbert, Victor ^b,c  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d RANCHO LOS AMIGOS NATIONAL REHABILITATION CENTER   (United States)

^e LAC USC MEDICAL CENTER   (United States)

Author keywords

Aging; Cardiovascular disease; Cardiovascular risk factor; Renal insufficiency; Vitamin B12

Indexed keywords

HOMOCYSTEINE;

ADULT; AGE; ARTICLE; BLOOD SAMPLING; CAUCASIAN; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ETHNOLOGY; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; OUTCOMES RESEARCH; POPULATION RESEARCH; PROTEIN BLOOD LEVEL; RACE; SEX DIFFERENCE; SPINAL CORD INJURY; STATISTICAL ANALYSIS; STRATIFICATION; AGED; BLOOD; CORONARY ARTERY ATHEROSCLEROSIS; MIDDLE AGED; REHABILITATION CENTER; RISK ASSESSMENT; UNITED STATES;

ADULT; AGE FACTORS; AGED; CALIFORNIA; CORONARY ARTERIOSCLEROSIS; FEMALE; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; REHABILITATION CENTERS; RISK ASSESSMENT; SEX FACTORS; SPINAL CORD INJURIES;

EID: 0035379354     PISSN: 10790268     EISSN: None     Source Type: Journal    
DOI: 10.1080/10790268.2001.11753559     Document Type: Article

References (49)

1. Mudd SH, Levy HL, Skovby F. Disorders of transsulfuration. In: Scriver CR, Beadet AL, Sly WS, Valle D, eds. The Metabolic Basis for Inherited Diseases. New York, NY: McGraw-Hill; 1989:693-734.
2. 12. In: Ziegler EE, Filer LJ, eds. Present Knowledge in Nutrition. 7th ed. Washington, DC: International Life Sciences Institute; 1996:191-205.
3. Herbert V. Folic acid. In: Shils ME, Olson JA, Shike M, Ross AC, eds. Modern Nutrition in Health & Disease. 9th ed. Philadelphia, Pa: Williams & Wilkins; 1999:433-446.
4. Bolander-Gouaille C. Focus on Homocysteine. Paris, France: Springer, 2000.
5. Finkelstein JD. Homocysteine: a history in progress. Nutr Rev. 2000;58:193-204.
6. 12 supplements. Am J Clin Nutr. In press.
7. Malinow MR, Kang SS, Taylor LM, et al. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circ Res. 1989;79:1180-1188.
8. Brattstrom L, Israelsson B, Norrving B, et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease: effects of pyridoxine and folic acid treatment. Atherosclerosis. 1990;81:51-60.
9. Molgaard J, Malinow MR, Lassvik C, Holm AC, Upson D, Olsson AL. Hyperhomocysteinemia: an independent risk factor for intermittent claudication. J Intern Med. 1992;23:273-279.
10. Brattstrom L, Israelsson B, Hultberg BJ. Plasma homocysteine and methionine tolerance in early-onset vascular disease. Haemostasis. 1989;19(suppl 1):35-44.
11. Coull BM, Malinow MR, Beamer N, et al. Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke. Stroke. 1990;1:215-220.
12. Brattstrom L, Lindgren A, Israelsson B, et al. Hyperhomocysteinaemia in stroke: prevalence, cause and relationship to type of stroke and stroke risk factors. Eur J Clin Invest. 1992;22:214-221.
13. Wilcken DEL, Reddy SG, Gupta VJ. Homocysteinemia, ischemic heart disease and the carrier state for homocystinuria. Metabolism. 1983;32:363-370.
14. Israelsson B, Brattstrom L, Hultberg BJ. Homocysteine and myocardial infarction. Atherosclerosis. 1988;71:227-233.
15. Murphy-Chutorian DR, Wexman MP, Grieco AJ, et al. Methionine intolerance: a possible risk factor for coronary artery disease. J Am Coll Cardiol. 1985;6:725-730.
16. Malinow MR, Sexton G, Averbauch M, et al. Homocyst(e)inemia in daily practice: levels in coronary heart disease. Coron Artery Dis. 1990;1:215-220.
17. Genest JJ, McNamara JR, Salem DN, Wilson PW, Schaefer EJ, Malinow MR. Plasma homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol. 1990;16:1114-1119.
18. Wu LL, Wu J, Hunt SC, et al. Plasma homocyst(e)ine as a risk factor for early familial coronary artery disease. Clin Chem. 1994;40:552-561.
19. Whiteneck GG, Charlifue SW, Frankel HL. Mortality, morbidity, and psychosocial outcomes of persons spinal cord injured more than 20 years ago. Paraplegia. 1992;30:617-630.
20. Bauman WA, Spungen AM. Disorders of carbohydrate and lipid metabolism in veterans with paraplegia or quadriplegia: a model of premature aging. Metabolism. 1994;43:749-756.
21. Bauman WA, Adkins RH, Spungen AM, Waters RL. The effect of residual neurological deficit on oral glucose tolerance in persons with chronic spinal cord injury. Spinal Cord. 1999;37:765-771.
22. Bauman WA, Spungem AM, Zhong YG, Rothstein JL, Petry C, Gordon SK. Depressed serum high density lipoprotein cholesterol levels in veterans with spinal cord injury. Paraplegia. 1992;30:697-703.
23. Bauman WA, Adkins RH, Spungen AM, et al. Is immobilization associated with an abnormal lipoprotein profile? Observations from a diverse cohort. Spinal Cord. 1999;37:485-493.
24. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
25. Castelli WP. Epidemiology of coronary heart disease: the Framingham study. Am J Med. 1984;76:4-12.
26. Goldbourt U, Medalie JH. High density lipoprotein cholesterol and incidence of coronary heart disease: the Israeli ischemic heart disease study. Am J Epidemiol. 1979;109:296-308.
27. Yekutiel M, Brooks ME, Ohry A, Yarom J, Carel R. The prevalence of hypertension, ischemic heart disease and diabetes in traumatic spinal cord injured patients and amputees. Paraplegia. 1989;27:58-62.
28. Malinow MR. Homocyst(e)ine and arterial occlusive diseases. J Intern Med. 1994;236:603-617.
29. Stamler JS, Slivka A. Biological chemistry of thiols in the vasculature and in vascular-related disease. Nutr Rev. 1996;54:1-30.
30. Stampfer MJ, Mailinow R, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992;268:877-881.
31. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324:1149-1155.
32. Araki A, Sako Y. Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr. 1987;422:43-52.
33. Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM. Homocysteine and ischemic heart disease: results of prospective study with implications regarding prevention. Arch Intern Med. 1998,158:862-867.
34. Lussier-Cacan S, Xhignesse M, Piolot A, Selhub J, Davignon J, Genest J. Plasma total homocysteine in healthy subjects: sex-specific relation with biological traits. Am J Nutr. 1996;64:587-593.
35. Mayer O Jr, Simon J, Rosolova H. Gender differences in serum homocysteine levels and associated factors [in Czech]. Cas Lek Cesk. 1999;138:525-527.
36. Brattstom L, Lindgren A, Israelsson B, Andersson A, Hultberg B. Homocysteine and cysteine: determinants of plasma levels in middle-aged and elderly subjects. J Intern Med. 1994;236:633-641.
37. Jacques PF, Rosenberg IH, Selhub J, et al. Serum total homocysteine concentrations in adolescent and adult Americans: results from the third National Health and Nutrition Examination Survey. Am J Clin Nutr. 1999;69:482-489.
38. 12 serum concentrations in 528 apparently healthy human subjects of ages 12-94. J Gerontol. 1957;12:32-38.
39. 12 Deficiency. London, UK: Royal Society of Medicine, 1999, Round Table Series No. 66.
40. Selhub J, Jacques PF, Rosenberg IH, et al. Serum total homocysteine concentrations in the third National Health and Nutrition Examination Survey (1991-1994): population reference ranges and contribution of vitamin status to high serum concentrations. Ann Intern Med. 1999;131:331-339.
41. 12 to any folate fortification or supplementation. Am J Clin Nutr. 1997;65:572-573.
42. Carmel R, Green R, Jacobsen DW, Rasmussen K, Florea M, Azen C. Serum cobalamin, homocysteine, and methylmalonic acid concentrations in a multiethnic elderly population: ethnic and sex differences in cobalamin and metabolite abnormalities. Am J Clin Nutr. 1999;70:904-910.
43. Bauman WA, Raza M, Chayez Z, Machac J. Tomographic thallium-201 myocardial perfusion imaging after intravenous dipyridamole in asymptomatic subjects with quadriplegia. Arch Phys Med Rehab. 1993;74:740-744.
44. Bauman WA, Raza M, Spungen AM, Machac J. Upper ergometry cardiac stress testing with thallium-201 imaging in paraplegia. Arch Phys Med Rehabil. 1994;75:946-950.
45. Bauman WA, Adkins RH, Spungen AM, Kemp BJ, Waters RL. The effect of residual neurological deficit on serum lipoproteins in individuals with chronic spinal cord injury. Spinal Cord. 1998;36;13-17.
46. Boushey Q, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995;274:1049-1057.
47. Bauman A, Owen N. Habitual physical activity and cardiovascular risk factors. Med J Aust. 1991;154:22-28.
48. 12 decreases homocysteine and methymalonic acid but also serum folate in patients with end-stage renal disease. Metabolism. 1999;48:631-635.
49. Beaulieu AJ, Gohh RY, Selhub J, Han H. Enhanced reduction of fasting total homocysteine levels with supraphysiological verses standard multivitamin dose folic acid supplementation in renal transplant recipients. Arterioscier Thromb Vasc Biol. 1999;19:2918-2921.